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Purpose: The aim of this study was to evaluate the effect of Helicobacter pylori (H. pylori) treatment on remission of
idiopathic central serous chorioretinopathy.
Methods: Twenty-five patients with idiopathic central serous chorioretinopathy (ICSCR) who were infected with H.
pylori were treated with an anti-H. pylori treatment; another twenty-five patients with the same clinical presentations
served as the control. Baseline examination and follow up visits at 2, 4, 6, 8, 12, and 16 weeks after the onset of treatment
included visual acuity testing and subretinal fluid measurement. The difference between mean visual acuity at the end of
16 weeks and the time of subretinal fluid reabsorption was compared between the two groups.
Results: Subretinal fluid reabsorption time was 9.28±3.20 weeks in the treatment group and 11.63±3.18 weeks in the
control group, which was statistically significant (p=0.015). After 16 weeks, mean visual acuity improved to 0.003±0.01
(logMAR) in the treatment group and 0.004±0.02 (logMAR) in the control group. This improvement did not represent a
statistically significant difference (p=0.97).
Conclusions:  An  anti-H.  pylori  treatment  regimen  is  effective  in  the  treatment  of  idiopathic  central  serous
chorioretinopathy patients and anti-H. pylori treatment can provoke the faster reabsorption of subretinal fluid.
Typically,  idiopathic  central  serous  chorioretinopathy
(ICSCR)  is  defined  as  a  neurosensory  serous  retinal
detachment  of  unknown  origin  that  affects  the  macula.  It
preferentially  afflicts  young  and  middle-aged  adults  and
occurs in men more often than in women [1]. Recurrences
have  been  documented  in  30%–50%  of  cases  [2,3].  The
precise pathophysiology of ICSCR is still poorly understood,
although  sympathomimetic  agents  [4],  systemic
corticosteroid therapy [5], type A characters [6], uncontrolled
systemic hypertension, pregnancy, and allergic respiratory
disease [7] have been reported as potential associated risk
factors  for  the  disease.  The  disease  often  resolves
spontaneously, but sometimes recurs or becomes chronic [8,
9]. Piccolino et al. [10] demonstrated changes in the foveal
photoreceptor layer in ICSCR that were highly correlated with
loss  of  visual  acuity  after  macular  reattachment.  The
photoreceptors are expected to die when detachment separates
them  from  the  retinal  pigment  epithelium  and  the
choriocapillaries, their source of oxygen and nutrients. A long
duration  of  ICSCR  is  associated  with  macular  zone
photoreceptor  loss  and  limited  visual  prognosis  after
reattachment. There is not a definitive treatment for ICSCR
and counseling alone does not satisfy most young patients;
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thus, some form of medication, such as tranquilizers and β-
blockers, are administered and some patients are treated by
laser photocoagulation, as that is the only effective palliative
measure. Laser photocoagulation may be considered for cases
in which ICSCR persists beyond 3–4 months. However, laser
therapy has certain limitations, for example, the leakage site
is  too  close  to  the  center  of  the  fovea  for  laser
photocoagulation in some patients and some patients have
post laser choroidal neovascularization (CNV) complications.
The method of properly treating ICSCR to shorten the course
of serous detachment remains to be determined because the
precise etiology of disease is unknown. Helicobacter pylori
(H. pylori) is a Gram-negative bacterium of spiral appearance
that is associated with multiple digestive and extra digestive
pathologies  [11].  H.  pylori  gastric  infection  has  been
implicated  as  an  important  factor  in  occlusive  arterial
pathology. It is suspected that ICSCR is due to a multifocal
vascular occlusive disease of choriocapillaries. Currently, the
possible  physiologic  relationship  between  ICSCR  and  H.
pylori is a controversial topic on which several studies have
been published in recent years [12]. A case report of ICSCR
in a 43 year-old man documented that recurrences of the
disease  were  always  associated  with  the  presence  of  H.
pylori and resolution of ICSCR and recovery of visual acuity
were correlated significantly with successful eradication of
the bacterium using conventional antimicrobial triple therapy
(amoxicillin,  clarithromycin,  and  omeprazole)  [13].  This
paper aims at establishing a possible pathogenic relationship
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99between gastric H. pylori infection and ICSCR. The current
study evaluates the effect of H. pylori treatment on remission
of ICSCR.
METHODS
During a randomized case controlled clinical trial study, we
evaluated a group of patients with ICSCR who were referred
to  our  referral  center,  the  Nikookari  Eye  Hospital—the
department of ophthalmology at Tabriz University of Medical
Sciences—over a period of 23 months between February 2008
and January 2010.
Clinical  ICSCR  diagnosis  was  confirmed  by  optical
coherence tomography (OCT) and fluorescein angiography.
The  diagnosis  was  established  based  on  neurosensory
detachment with one or more sites of leakage at the level of
the retinal pigment epithelium (RPE) without other causes of
exudation, such as CNV, inflammation, or infiltration.
We evaluated a total of 58 patients with ICSCR. Among
these patients, 50 patients who had ICSCR, were infected with
H. pylori, and met our inclusion criteria were included in the
study. The patients were divided in two groups using random
allocation software. H. pylori infection was assessed by the
C13-urea breath test. At the end of treatment course, patients
who received H. pylori eradication regiment underwent urease
breath test (UBT) testing to evaluate the effectiveness of the
anti-H.  pylori  treatment.  The  inclusion  criteria  were  as
follows: To accept participation in the study by signing an
informed consent; not having been treated with antibiotics, a
proton pomp inhibitor, corticosteroids, or sympathomimetic
drugs for 3 months before the study; and having no history of
previous ocular surgery. Twenty-five patients were treated
with  an  H.  pylori  eradication  regiment  including
metronidazole and amoxicillin 500 mg three times daily for
two weeks and omeprazole once daily for 6 weeks. Another
25  patients  served  as  a  control  group  and  received  no
medication. The patients who had persistent subretinal fluid
after  16  weeks  received  laser  photocoagulation  therapy.
Baseline examination and follow-up visits at 2, 4, 6, 8, 12, and
16 weeks after the onset of treatment included testing of best
corrected visual acuity and evaluation of the amount of the
neurosensory or RPE detachment, measured by OCT (Stratus
OCT3; Carl Zeiss Meditec Inc., Dublin, CA). The latter was
determined by manually placing the calipers and using the
scan with the highest serous retinal detachment area.
Statistical analysis: Independent samples t-test, χ2, or
Fishers Exact test were used to compare results between the
groups, and the Weibull survival model was used to determine
the early response to treatment. All statistical tests were two-
sided.  A  P  value  of  0.05  was  considered  statistically
significant.  Statistical  analysis  was  performed  using  the
statistical package SPSS.15/win. This study has been cited at
the Clinical trial website (ID: NCT00817245).
RESULTS
Mean patient age was 32.54±4.57 years old (range 24–41) in
the treatment group and 34.24±4.78 years old (range 27–43)
in the control group (p=0.20). The female to male ratio was
4/21 in the treatment group and 5/20 in the control group.
Mean interval between beginning of symptoms and treatment
was11.96±8.15 days in the treatment group and 9.20±6.50
days in the control group (p=0.18). All patients responded to
eradication treatment and the results of the urea breath test
were  negative  in  all  patients  in  the  treatment  group.  No
systemic adverse effects of medication were observed.
In the treatment group, 23 patients had pure neurosensory
detachment and 2 patients showed both neurosensory and
RPE detachment. In the control group, 22 patients had pure
neurosensory  detachment  and  3  patients  showed  both
neurosensory and RPE detachment.
Average  neuroretinal  and/or  pigment  epithelial
detachment  at  baseline  was  305.45±161.48  µm  in  the
treatment group and 290.00±164.38 µm in the control group.
The differences at baseline were not statistically significant
(p=0.73); the subretinal fluid reduction trend is presented in
Figure 1 and Table 1. The subretinal fluid reabsorption time
was 9.28±3.20 weeks in the treatment group and 11.63±3.18
weeks in the control group, which was statistically significant
(p=0.015). The Weibull survival model showed that the time
of response to medication was statistically different between
the two groups (p=0.04); in the treatment group, subretinal
fluid reached zero earlier than the control group. Laser therapy
was performed due to persistent subretinal fluid in 3 control
group patients and 1 treatment group patient (Table 2).
At  baseline,  mean  visual  acuity  (VA)  was  0.10±0.05
(logMAR) in the treatment group and 0.09±0.05 (logMAR)
in  the  control  group.  The  differences  were  not  clinically
significant (p=0.83). Sixteen weeks later, mean VA improved
to  0.003±0.01  (logMAR)  in  the  treatment  group  and
0.004±0.02  (logMAR)  in  the  control  group.  This
improvement  did  not  represent  a  statistically  significant
difference (p=0.97).
DISCUSSION
Idiopathic  central  serous  chorioretinopathy  is  a  macular
serous detachment secondary to one or more focal lesions of
the RPE, typically affects young men, and usually resolves
with  good  visual  prognosis,  but  sometimes  can  become
chronic and progressive with severe visual loss [14].
The pathogenesis and treatment of ICSCR is still poorly
understood. The disease is characterized by breakdown of the
outer retinal barrier, with leakage of fluid through a defect in
the  retinal  pigment  epithelium  into  the  subretinal  space,
resulting in a serous neurosensory detachment [15].
A correlation between ICSCR and H. pylori infection has
recently been hypothesized [12-16]. This association is still
unclear. A possible explanation might arise indirectly from
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100the published hypothesis of a pathogenic link between H.
pylori infection and atherosclerosis. A cross-reactivity of anti-
cagA  antibodies  with  vascular  wall  antigen  has  been
postulated  in  another  study,  and  the  immunoglobulin  G
antibody response to multiple pathogens has been considered
as  an  independent  risk  factor  for  endothelial  dysfunction
[17-19]. The association between coronary artery disease and
several infectious pathogens such as H. pylori was found to
be  modulated  by  the  interleukin  (IL)-6/G-174C
polymorphism, this interaction being mediated by variations
in serum IL-6 levels [20].On the other hand, a decreased
foveal choroidal blood flow has been demonstrated by laser
Doppler  flowmetry  and  using  fluorescein  and  ICG
angiography with confocal scanning laser ophthalmoscopy.
These non-perfuse areas probably result from filling delays of
the  choroidal  arteries  and  the  choriocapillaries  [21].  The
already  mentioned  focal  occlusion  of  the  choroidal
microcirculation together with interaction between H. pylori
and vascular endothelium could explain the mechanism of
choroidal  ischemia  and  the  development  of  ICSCR  in  H.
pylori infected patients. In a prospective study, with 16 ICSCR
patients in the south of France, Mauget-Faysse et al. [22]
detected  H.  pylori  infection  in  56.3%  of  patients.  This
percentage is much higher than the 27.5% of the control group.
Figure 1. The trend of subretinal fluid
reduction  measured  by  optical
coherence tomography at baseline and
follow up visits at 2, 4, 6, 8, 12, and 16
weeks after the onset of treatment. The
sample size was 25 cases for treatment
group and 25 cases for control group
throughout the study.
TABLE 1. MEAN SUBRETINAL FLUID MEASURED BY OPTICAL COHERENCE TOMOGRAPHY AT BASELINE AND FOLLOW UP VISITS AT
BASELINE 2, 4, 6, 8, 12, AND 16 WEEKS AFTER THE ONSET OF TREATMENT.
Follow up (weeks)
Subretinal fluid level (µm)
p-value Case (n=25) Control (n=25)
0 305.46±161.48 290.00±164.38 0.73
2 198.31±112.51 227.32±126.12 0.39
4 130.77±80.50 172.76±109.28 0.12
6 54.88±53.95 110.04±78.28 0.21
8 24.35±33.70 65.84±72.05 0.11
12 6.81±20.41 26.64±6.70 0.1
16 2.92±14.90 17.68±54.36 0.18
             *Data are presented as Mean±SD.
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101The  other  complementary  study,  which  was  done  by
Ahnoux-Zabsone et al. [23], aimed to verify the results of
Mauget-Faysse’s study. The difference in the prevalence of
H.  pylori  between  the  study  population  (39.7%)  and  the
overall  population  of  58,419,710  inhabitants  of  France  in
1999 (25.4%) was found statistically significant.
Asensio-Sachez et al. [24] showed a possible statistical
association between H. pylori gastric infection and ICSCR. In
their  study,  the  difference  in  the  prevalence  of  H.  pylori
between the ICSCR group (68.75%) and the control group
(30%) was found to be statistically significant (p<0.05), and
they regarded H. pylori infection as a risk factor in ICSCR
patients.
In  cases  of  recent  onset,  central  vision  is  minimally
affected and usually returns to normal after reabsorption of
the  subretinal  fluid.  In  recurrent  and  chronic  cases,
progressive and irreversible visual decline can be associated
with the development of central retinal pigment epithelium
atrophy, cystoid macular degeneration, and foveal atrophy
[8,9]. We selected the acute cases of ICSCR with no history
of chronic or recurrent ICSCR. There was no cystoid change
at the macula due to chronicity, and this may result in no
difference in visual acuity between the two groups; however,
the  subretinal  fluid  reabsorption  time  was  greater  in  the
control group than the treatment group, which was statistically
significant and will play a significant role in the outcome of
disease since a long duration of ICSCR is associated with
macular zone photoreceptor loss [10]. On the other hand, in 3
control group patients and 1 treatment group patient, laser
therapy was performed due to persistent subretinal fluid.
All  of  the  above-mentioned  studies  showed  that  H.
pylori could be a risk factor in patients with ICSCR. In this
study, our results showed that an anti-H. pylori treatment
regimen is effective in the treatment of ICSCR patients and
that  anti-H.  pylori  treatment  can  provoke  the  faster
reabsorption of subretinal fluid. Thus, upon these results, the
association between H. pylori and ICSCR became stronger
than previously thought. This new finding could lead to a new
therapeutic approach to ICSCR.
We recommend further studies with larger numbers of
patients, longer follow-up periods, and use of other functional
tests, such as color vision, Amsler, Watzke-Allen, to evaluate
the efficacy of H. pylori treatment on ICSCR.
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